Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05953584RecruitingPhase 2
Etavopivat for preventing stroke risk in sickle cell children
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Raipur, ChhattisgarhAges 12–16 - NCT05962398Enrolling by invitation
Follow-up study for men previously treated with CSL222
This study checks long-term safety and outcomes in men with hemophilia B who previously received CSL222. It may help your care team better understand how well the treatment lasts over many years.
Phoenix, ArizonaAges 18 years+ - NCT05943522Recruiting
Study of asciminib in adults with Ph+ CML on Scemblix
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
Wŏnju, Gangwon-doAges 18–100 - NCT05951777RecruitingPhase 2
Stem cells from your own fat for chronic brain injury
This trial tests whether stem cells taken from your own fat and given through an IV can help people with long-term brain damage from a head injury. It is for adults who have not gotten better with standard treatments.
Houston, TexasAges 18–55 - NCT05949125RecruitingPhase 1
Immune cell therapy for advanced acute myeloid leukemia
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
Ulm, Baden-WurttembergAges 18 years+ - NCT05948943RecruitingPhase 2/Phase 3
Alpelisib for lymphatic malformations with a PIK3CA change
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
Oakland, CaliforniaAges birth–100 years - NCT05566054RecruitingPhase 2
Newly diagnosed AML-M5 treated with VAC drug combination
This Phase 2 trial studies a combination of Venetoclax, Azacitidine, and Chidamide (VAC) for newly diagnosed acute monocytic leukemia (AML-M5). It may help people who cannot safely receive standard “intensive chemotherapy” because of age or other health problems.
Suzhou, JiangsuAges 18 years+ - NCT05940961RecruitingPhase 2
Inotuzumab for MRD-positive B-cell leukemia after transplant
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
Suzhou, JiangsuAges 15–65 - NCT05936580RecruitingPhase 4
Nuwiq dosing for girls and women with hemophilia A surgery
This trial studies how to dose Nuwiq (a factor medicine) and track outcomes in girls and women with hemophilia A who need major surgery. It may help confirm the best way to manage bleeding risk around surgery.
San Antonio, TexasAges 12 years+ - NCT05912517RecruitingPhase 3
Nipocalimab for high-risk pregnancy blood disease
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
La Jolla, CaliforniaAges 18–45 - NCT05935215RecruitingPhase 3
Switch from anti-C5 shots to iptacopan for aHUS
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
Nanjing, JiangsuAges 18–100 - NCT05927571RecruitingPhase 1
Cevostamab and elranatamab combination study for relapsed myeloma
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
Camperdown, New South WalesAges 18 years+ - NCT05935358RecruitingPhase 4
Nuwiq added around surgery for people with hemophilia A
This Phase 4 study looks at how well Nuwiq works to manage bleeding risk around the time of major elective surgery in people with severe hemophilia A who already take emicizumab to prevent bleeds. It may help your surgical team plan safer blood-clotting support during and after surgery.
Dallas, TexasAges 12 years+ - NCT05932680RecruitingPhase 2
Continue teclistamab for a limited time in responding patients
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
Little Rock, ArkansasAges 18 years+ - NCT05921253RecruitingEarly Phase 1
Check a brain-heart device to reduce chemo heart risk
This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.
Oklahoma City, OklahomaAges 18–99 - NCT05939180RecruitingPhase 2/Phase 3
Compare two induction treatments for newly diagnosed high-risk AML
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
Suzhou, JiangsuAges 18–64 - NCT05916638Recruiting
Testing a breathing pattern in people with sarcoidosis and TB
This trial looks at a specific “MoMa signature” related to breathing or lung signals in adults who have been diagnosed with both sarcoidosis and tuberculosis. It may help researchers understand how these conditions affect the body and improve how patients are monitored.
ParisAges 18 years+ - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05917405RecruitingPhase 2
Clofarabine vs fludarabine for AML before stem cell transplant
This Phase 2 study compares two chemotherapy medicines—clofarabine and fludarabine—given at a reduced intensity before an allogeneic stem cell transplant. It aims to see which regimen works better and is safer for people with AML who are eligible for this transplant approach.
Nantes, Loire AtlantiqueAges 18–99 - NCT05922501RecruitingPhase 2
Test four medicines for relapsed multiple myeloma
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Boston, MassachusettsAges 18 years+ - NCT05916469Recruiting
Hormone treatment for heavy periods in teens and young adults
This trial studies how a progestin hormone—given as an IUD or tablets—can help reduce heavy menstrual bleeding in people with certain bleeding-related conditions. It may help you by testing whether the treatment works and is practical for your situation.
Palo Alto, CaliforniaAges 10–24 - NCT05940272Recruiting
Communication training for doctors treating large B-cell lymphoma
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
New York, New YorkAges 18 years+ - NCT05934084Recruiting
Lifestyle plan for heart and health after lymphoma remission
This trial tests a structured lifestyle and survivorship care plan for people who finished treatment for certain lymphoma types and are now in long-term remission. The goal is to support long-term health (including heart-related monitoring) and reduce future risks.
Ancona, AnconaAges 18–50
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.